share_log

10-K: FY2023 Annual Report

10-K: FY2023 Annual Report

10-K：2023财年年报
美股SEC公告 ·  04/16 17:11
Moomoo AI 已提取核心信息
SeaStar Medical, a medical technology company, reported a net loss of $26.2 million for the year ended December 31, 2023, compared to a net loss of $12.2 million in the previous year, marking a 115% increase. The company's accumulated deficit rose to approximately $114.7 million from $88.5 million year-over-year. Research and development expenses increased by 139% to $5.973 million, driven by clinical trial expenses and payroll, while general and administrative expenses grew by 19% to $8.237 million due to higher insurance, SEC reporting fees, and legal costs. SeaStar Medical has not generated significant revenue from commercialized products, with its operations primarily funded through equity securities, convertible debt, and grants. The company's cash position as of December 31, 2023, was approximately $0.2 million, up from $0.0 million the previous year. SeaStar Medical's future plans include continuing clinical development of its Selective Cytopheretic Device (SCD) for FDA approval and eventual commercialization. However, the company acknowledges the need for additional capital to fund operations and the uncertainty of raising such capital on favorable terms, if at all.
SeaStar Medical, a medical technology company, reported a net loss of $26.2 million for the year ended December 31, 2023, compared to a net loss of $12.2 million in the previous year, marking a 115% increase. The company's accumulated deficit rose to approximately $114.7 million from $88.5 million year-over-year. Research and development expenses increased by 139% to $5.973 million, driven by clinical trial expenses and payroll, while general and administrative expenses grew by 19% to $8.237 million due to higher insurance, SEC reporting fees, and legal costs. SeaStar Medical has not generated significant revenue from commercialized products, with its operations primarily funded through equity securities, convertible debt, and grants. The company's cash position as of December 31, 2023, was approximately $0.2 million, up from $0.0 million the previous year. SeaStar Medical's future plans include continuing clinical development of its Selective Cytopheretic Device (SCD) for FDA approval and eventual commercialization. However, the company acknowledges the need for additional capital to fund operations and the uncertainty of raising such capital on favorable terms, if at all.
医疗科技公司SeaStar Medical报告称，截至2023年12月31日的一年中出现净亏损2620万美元，比上一年的净亏损1220万美元增长115%。公司的累计赤字从去年的8850万美元增加至约11470万美元。研发费用增加139%，达到597.3万美元，主要是由于临床试验费用和人员工资增加，而一般和管理费用由于保险费、SEC报告费和法律费用增加19%，达到823.7万美元。SeaStar Medical尚未从商业化产品中获得重大收入，其运营主要通过股权证券、可转换债券和拨款进行融资。截至2023年12月31日，该公司的现金余额约为20万美元，而上一年为0万美元。SeaStar Medical的未来计划包括继续开发其选择性细胞谷物装置（SCD）以获得FDA批准和最终商业化。然而，该公司承认需要额外的资金支持其运营，并且筹集这样的资金是否有利可图仍存在不确定性。
医疗科技公司SeaStar Medical报告称，截至2023年12月31日的一年中出现净亏损2620万美元，比上一年的净亏损1220万美元增长115%。公司的累计赤字从去年的8850万美元增加至约11470万美元。研发费用增加139%，达到597.3万美元，主要是由于临床试验费用和人员工资增加，而一般和管理费用由于保险费、SEC报告费和法律费用增加19%，达到823.7万美元。SeaStar Medical尚未从商业化产品中获得重大收入，其运营主要通过股权证券、可转换债券和拨款进行融资。截至2023年12月31日，该公司的现金余额约为20万美元，而上一年为0万美元。SeaStar Medical的未来计划包括继续开发其选择性细胞谷物装置（SCD）以获得FDA批准和最终商业化。然而，该公司承认需要额外的资金支持其运营，并且筹集这样的资金是否有利可图仍存在不确定性。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

独立文件5  查看翻译

独立文件6  查看翻译

独立文件7  查看翻译

独立文件8  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息